CervoMed reported a narrowed net loss of $5.9 million for the third quarter of 2026, compared to $7.7 million in the same period last year. The company recognized zero grant revenue this quarter following the completion of its Phase 2b RewinD-LB trial in mid-2025. With a cash position of $19.6 million, management expects to fund its current operating plan and capital requirements through the third quarter of 2027.

Key Highlights

  • Cash, cash equivalents, and marketable securities totaled $19.6 million as of September 30, 2026, sufficient to fund operations for one year.
  • Research and development expenses decreased 38% to $3.7 million, primarily driven by the conclusion of the RewinD-LB clinical trial.
  • Enrollment was completed for the 45-patient Phase 2a RESTORE trial in stroke recovery, with topline results anticipated by the end of 2026.
  • Presentation of 24-week biomarker data from the Phase 2a trial in nonfluent variant primary progressive aphasia (nfvPPA) is scheduled for mid-November 2026.